Fig. 6

Hepcidin/FPN1 and TFR1/FT phenotype dyads in ductal carcinoma in situ lesions (DCIS). A semi-quantitative method of assessing the immunoexpression in the TMA sections was applied by multiplying the area and intensity staining scores, as described in materials and methods. The scores ranged from 0 to 15. Graphs show Mean ± SEM. Significant differences are shown for comparison with the precedent group *p < 0.05, **p < 0.01, ***p < 0.001, Mann Whitney’s U test; a Immunoexpression score for breast epithelial cells in DCIS pure lesions and DCIS lesions in IDC for Hepcidin (n = 35), FPN1 (Ferroportin 1, n = 35), TFR1 (Transferrin Receptor 1, n = 32) and FT (Ferritin, n = 36); b Immunoexpression score for macrophages in DCIS pure lesions and DCIS lesions in IDC for Hepcidin (n = 28), FPN1 (Ferroportin 1, n = 27), TFR1 (Transferrin Receptor 1, n = 30) and FT (Ferritin, n = 33); c Immunoexpression score for lymphocytes in DCIS pure lesions and DCIS lesions in IDC for Hepcidin (n = 26), FPN1 (Ferroportin 1, n = 31), TFR1 (Transferrin Receptor 1, n = 30) and FT (Ferritin, n = 33)